Suma Krishnan Sells 25,000 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total value of $4,944,000.00. Following the sale, the insider now owns 1,500,882 shares in the company, valued at $296,814,424.32. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Krystal Biotech Trading Up 3.0 %

Shares of NASDAQ KRYS opened at $201.58 on Friday. Krystal Biotech, Inc. has a one year low of $93.95 and a one year high of $219.34. The business has a 50-day moving average price of $196.03 and a two-hundred day moving average price of $178.64. The firm has a market capitalization of $5.79 billion, a PE ratio of 107.80 and a beta of 0.82.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, August 5th. The company reported $0.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.50 by $0.03. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. The firm had revenue of $70.28 million during the quarter, compared to analysts’ expectations of $65.27 million. During the same quarter last year, the firm earned ($1.25) earnings per share. The business’s revenue for the quarter was up 70283900.0% on a year-over-year basis. Research analysts anticipate that Krystal Biotech, Inc. will post 3.13 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Evercore ISI lifted their target price on Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a research report on Monday, August 12th. Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. Chardan Capital raised their target price on Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research note on Monday, August 5th. Stifel Nicolaus raised their target price on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, HC Wainwright upped their price objective on shares of Krystal Biotech from $200.00 to $221.00 and gave the company a “buy” rating in a research note on Wednesday, August 28th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $196.75.

Hedge Funds Weigh In On Krystal Biotech

Several hedge funds and other institutional investors have recently added to or reduced their stakes in KRYS. Jamison Private Wealth Management Inc. acquired a new position in shares of Krystal Biotech during the 2nd quarter valued at about $28,000. GAMMA Investing LLC grew its holdings in Krystal Biotech by 160.3% during the second quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock valued at $28,000 after purchasing an additional 93 shares during the last quarter. Key Financial Inc bought a new position in shares of Krystal Biotech in the second quarter valued at approximately $28,000. Blue Trust Inc. lifted its stake in shares of Krystal Biotech by 2,328.6% in the second quarter. Blue Trust Inc. now owns 170 shares of the company’s stock worth $30,000 after buying an additional 163 shares during the last quarter. Finally, Quest Partners LLC acquired a new stake in shares of Krystal Biotech in the second quarter valued at about $71,000. Institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).